IDEXX LABORATORIES INC /DE (IDXX) Form 8-K — Aug 4, 2026
IDEXX Laboratories reported second quarter 2026 revenue of $1.22 billion, reflecting 10% reported growth and 9% organic growth. The company delivered EPS of $4.27, an 18% increase as reported, while operating margin expanded by 140 basis points to 35.0% driven by strong recurring revenue volume and operational productivity. Following the strong performance, management raised its full-year 2026 revenue outlook to a range of $4.70 billion to $4.745 million, an increase of $5 million at the midpoint. The full-year EPS outlook was increased to a range of $14.69 to $14.94, reflecting benefits from operational performance despite a $15 million foreign exchange headwind.
Key figures
- Eps
- $4.27
- Revenue
- $1,217 million
- Guidance
- Revenue $4,700 - $4,745 million, EPS $14.69 - $14.94
- Net Income
- $338.4 million
- Total Debt
- $968.9 million
- Cash Position
- $196.9 million
- Gross margin
- 64.0%
- Operating margin
- 35.0%
- Eps growth reported
- 18%
- Revenue growth organic
- 9%
- Revenue growth reported
- 10%
- Operating margin expansion bps
- 140
Price after filing
Close on the filing date to close N calendar days later (from $558.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.